VJHemOnc is committed to improving our service to you

COMy Virtual 2020 | MRD: the most relevant prognostic factor in myeloma

VJHemOnc is committed to improving our service to you

Bruno Paiva

Following his talk at the 2020 COMy virtual meeting, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses which patient with multiple myeloma should undergo measurable residual disease (MRD) monitoring, the rapid growth of the technique and it’s increasing importance. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter